AU2009314447A1 - Compositions and methods for the treatment of altered alpha-synuclein function - Google Patents

Compositions and methods for the treatment of altered alpha-synuclein function Download PDF

Info

Publication number
AU2009314447A1
AU2009314447A1 AU2009314447A AU2009314447A AU2009314447A1 AU 2009314447 A1 AU2009314447 A1 AU 2009314447A1 AU 2009314447 A AU2009314447 A AU 2009314447A AU 2009314447 A AU2009314447 A AU 2009314447A AU 2009314447 A1 AU2009314447 A1 AU 2009314447A1
Authority
AU
Australia
Prior art keywords
alkyl
substituted
alkenyl
piperazino
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009314447A
Other languages
English (en)
Inventor
Arasteh Ari Azhir
J. William Langston
Cliff A. Lingwood
Amy B. Manning-Bog
Michael S. Mcgrath
Birgitt Shule
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children HSC
Parkinsons Institute
Neuraltus Pharmaceuticals Inc
Original Assignee
Hospital for Sick Children HSC
Parkinsons Institute
Neuraltus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Sick Children HSC, Parkinsons Institute, Neuraltus Pharmaceuticals Inc filed Critical Hospital for Sick Children HSC
Publication of AU2009314447A1 publication Critical patent/AU2009314447A1/en
Priority to AU2014265137A priority Critical patent/AU2014265137A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009314447A 2008-11-14 2009-09-04 Compositions and methods for the treatment of altered alpha-synuclein function Abandoned AU2009314447A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014265137A AU2014265137A1 (en) 2008-11-14 2014-11-24 Compositions and methods for the treatment of altered alpha-synuclein function

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19924308P 2008-11-14 2008-11-14
US61/199,243 2008-11-14
PCT/US2009/056116 WO2010056413A2 (en) 2008-11-14 2009-09-04 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014265137A Division AU2014265137A1 (en) 2008-11-14 2014-11-24 Compositions and methods for the treatment of altered alpha-synuclein function

Publications (1)

Publication Number Publication Date
AU2009314447A1 true AU2009314447A1 (en) 2010-05-20

Family

ID=42170611

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009314447A Abandoned AU2009314447A1 (en) 2008-11-14 2009-09-04 Compositions and methods for the treatment of altered alpha-synuclein function

Country Status (9)

Country Link
US (2) US20120052053A1 (enExample)
EP (1) EP2361089A4 (enExample)
JP (2) JP2012508740A (enExample)
CN (1) CN102245180A (enExample)
AU (1) AU2009314447A1 (enExample)
BR (1) BRPI0920498A2 (enExample)
CA (1) CA2745451A1 (enExample)
GB (1) GB2480159A (enExample)
WO (1) WO2010056413A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505374A (ja) * 2007-11-29 2011-02-24 ザ・ホスピタル・フォー・シック・チルドレン リソソーム障害を処置するための組成物および方法
US9265735B2 (en) * 2010-11-30 2016-02-23 New York University Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof
EP2533051A1 (en) * 2011-06-06 2012-12-12 Centogene GmbH Method for the diagnosis of Gaucher's disease
EP2739304A4 (en) * 2011-08-04 2015-06-03 Univ Ramot PARTICLES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CN103120697B (zh) * 2011-11-18 2015-10-07 复旦大学 鳞片酸在制备抗肿瘤药物中的应用
CN103120696A (zh) * 2011-11-18 2013-05-29 复旦大学 羊角衣酸在制备抗肿瘤药物中的应用
CN104069263A (zh) * 2013-03-27 2014-10-01 中国科学院上海药物研究所 一种用于治疗阿尔茨海默病的制剂及其制备方法
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor
CN105796579A (zh) * 2014-12-31 2016-07-27 中国科学院兰州化学物理研究所 抗老年性脑痴呆药物
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use
CA3018745A1 (en) * 2016-03-25 2017-09-28 Genzyme Corporation Biomarkers of proteopathies and uses thereof
CN108348557A (zh) * 2016-03-28 2018-07-31 心悦生医股份有限公司 含有鞣酸的组合物及其用途
CN105748460B (zh) * 2016-04-07 2018-11-02 大连医科大学附属第二医院 一种治疗老年痴呆的药物
ES2650175B1 (es) * 2016-04-15 2019-02-04 Servicio Andaluz De Salud Tratamiento de enfermedades neurodegenerativas
US10064833B2 (en) 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
CN108143738A (zh) * 2016-12-02 2018-06-12 中国科学院大连化学物理研究所 一种治疗阿尔茨海默症的药物组合物及其制备和应用
CN107823198A (zh) * 2017-11-16 2018-03-23 黑龙江葆纳生物科技有限责任公司 北美圣草素在制备治疗阿尔茨海默病药物中的应用
KR20200097255A (ko) * 2017-12-07 2020-08-18 신유알엑스 인터내셔널 (타이완) 코포레이션 탄닌산 조성물을 제조하기 위한 개선된 풍부화 방법
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
US11766423B2 (en) 2018-03-01 2023-09-26 The Johns Hopkins University 2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a small molecule inhibitor of neutral sphingomyelinase 2 (nSMase-2) for the treatment of neurodegenerative and oncologic diseases
WO2020144753A1 (ja) * 2019-01-09 2020-07-16 公立大学法人大阪 神経変性疾患の予防又は治療薬
KR102102868B1 (ko) * 2019-05-14 2020-04-23 주식회사 노브메타헬스 고시페틴(Gossypetin)을 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
US11154531B2 (en) 2020-02-08 2021-10-26 Syneurx International (Taiwan) Corp. Compounds and pharmaceutical uses thereof
WO2021188575A1 (en) * 2020-03-16 2021-09-23 Coe William B Dietary supplement comprising aldehyde functional monoterpenoids
US10993958B1 (en) 2020-03-16 2021-05-04 William B. Coe Aldehyde functional monoterpenoids for the treatment of coronavirus infection
KR20230004765A (ko) 2020-04-23 2023-01-06 신유알엑스 인터내셔널 (타이완) 코포레이션 화합물 및 이의 약학적 용도
WO2022104011A1 (en) * 2020-11-12 2022-05-19 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
CN112870250B (zh) * 2021-01-21 2022-08-12 广东盛普生命科技有限公司 防治器官纤维化的组合物及其应用与制剂
CN112704680B (zh) * 2021-01-21 2022-08-02 广东盛普生命科技有限公司 预防和/或治疗器官纤维化的组合物及其应用与制剂
WO2024026390A2 (en) * 2022-07-28 2024-02-01 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases
KR20240023004A (ko) * 2022-08-12 2024-02-20 포항공과대학교 산학협력단 고시페틴을 포함하는 지방간 개선용 조성물
CN115417789B (zh) * 2022-09-03 2023-08-04 郑州大学 一种治疗帕金森氏病的化合物、其制备方法以及复方药物组合物和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
JP2007500219A (ja) * 2003-05-16 2007-01-11 アンビット バイオサイエンシス コーポレーション 複素環化合物およびその使用法
CN104771402A (zh) * 2005-06-08 2015-07-15 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
WO2007003941A1 (en) * 2005-07-06 2007-01-11 Cambridge Enterprise Limited Modulation of autophagy by calpain inhibition
DK1860101T3 (da) * 2006-05-24 2011-07-25 Amicus Therapeutics Inc Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf
AU2007260812B2 (en) * 2006-06-23 2012-08-16 Amicus Therapeutics, Inc. Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase
WO2008031831A2 (en) * 2006-09-12 2008-03-20 Neurosearch A/S Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein

Also Published As

Publication number Publication date
JP2012508740A (ja) 2012-04-12
GB201108374D0 (en) 2011-06-29
JP2015127343A (ja) 2015-07-09
CN102245180A (zh) 2011-11-16
CA2745451A1 (en) 2010-05-20
EP2361089A4 (en) 2012-08-22
EP2361089A1 (en) 2011-08-31
US20120052053A1 (en) 2012-03-01
GB2480159A (en) 2011-11-09
US20150044193A1 (en) 2015-02-12
BRPI0920498A2 (pt) 2019-09-24
WO2010056413A2 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
US20150044193A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION
US8252789B2 (en) Compositions and methods for treating lysosomal disorders
Lin et al. N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease
AU2017279780B2 (en) Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
Luan et al. The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice
van Echten-Deckert et al. Sphingolipid metabolism–an ambiguous regulator of autophagy in the brain
US20130023488A1 (en) Methods and compounds for reducing intracellular lipid storage
EP2714924B1 (en) HDAC Inhibitors for use in the treatment of Gaucher's disease, von Hippel-Lindau disease, phaeochromocytoma and paragangliomas.
Baek et al. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice
US7662838B2 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
WO2014179438A2 (en) Glycolipid inhibition using iminosugars
Jakobkiewicz-Banecka et al. Combined therapies for lysosomal storage diseases
US20220362189A1 (en) Combination therapy with acetyl-leucine and miglustat
LeVine et al. Substrate reduction therapy for krabbe disease: exploring the repurposing of the antibiotic D-Cycloserine
AU2014265137A1 (en) Compositions and methods for the treatment of altered alpha-synuclein function
US12029706B2 (en) Methods for treating mucopolysaccharidosis
US20050182020A1 (en) Ceramide de novo synthesis-based therapeutic and prophylactic methods, and related articles of manufacture
WO2009040816A1 (en) Methods of treating lysosomal storage disorders
AU2012308222A1 (en) Pterostilbene and statin combination for treatment of metabolic disease, cardiovascular disease, and inflammation
JP2025136965A (ja) 疼痛治療剤
Fan et al. Pharmacological chaperone therapy for fabry disease
HK1175400B (en) Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted